ACRIN
Biostatistics and Data Management Center of the American College of Radiology Imaging Network
(ACRIN)
Faculty: Gatsonis
(Director), Blume (Deputy
Director), Acharrya, Chen, Gareen, Liu
The American College of Radiology Imaging Network (ACRIN; www.acrin.org) is a cooperative group funded
by the Cancer Imaging Program of the National Cancer Institute to
conduct multi-center, interdisciplinary clinical evaluations of
diagnostic imaging in cancer. ACRIN began its operations in 1999 and
is now in its second funding cycle. The Center for Statistical
Sciences at Brown is home to the Biostatistics Center of the
network. Headquarters and data management operations are based at the
Philadelphia Office of the American College of Radiology.
The current research portfolio of ACRIN includes 11 trials in accrual
or follow-up, 4 trials in analysis, and 8 trials in development. The
network's research program covers all aspects of the role of imaging
in cancer, from early detection to diagnosis and staging, to disease
management and image guided treatment. The trials vary in size from
relatively small studies of developing imaging modalities (such as
magnetic resonance imaging spectroscopy) to very large studies of
modalities for the early detection of disease. The latter include the
Digital Mammography Screening Trial (DMIST), which enrolled 49,500
women and compared the diagnostic accuracy of digital and film
mammography, and the National Lung Screening Trial (NLST) which
enrolled more than 50,000 participants at high risk for lung cancer
and randomized them to annual screening with helical CT or x-ray.
More than 100 centers across the US, as well as centers in Canada
participate in ACRIN studies.
The Biostatistics Center of ACRIN provides methodologic leadership and
support to ACRIN investigators in the design, implementation, and
analysis of network studies. Center faculty and staff are integrally
involved in every step of the life of each protocol, from the early
development of ideas and concept sheets, to the final analysis of the
data and the preparation of reports and manuscripts. ACRIN faculty are
also engaged in research on statistical methods for the evaluation of
the performance of modalities in the early detection and diagnosis of
disease and in the prediction of the course of therapy.
Professors Constantine Gatsonis and Jeffrey Blume oversee the
operations of the Biostatistics and Data Management Center of
ACRIN. Professors Suddho Acharrya, Mei-Hsiu Chen, and Dawei Liu serve
as lead statisticians in ACRIN protocols. Professor Ilana Gareen
serves as an epidemiologist in several ACRIN studies. Quentin McMullen
is the administrative manager of the Biostatistics Center; Jean
Cormack, PhD, Lucy Hanna, MS MAT, Ben Herman, SM, Helga Marques, MS,
Karthik Meganathan, MS, JoRean Sicks, MS, Brad Snyder, MS, and Jing
Zhou, MS are the staff biostatisticians. Nancy Ciminelli, Rebecca
McVey, and Cheryl Souza work on the collection of quality of life data
in several of the ACRIN studies. Jim Patterson and Henry Robinson
provide informatics support for the Biostatistics Center. The Center's
administrative personnel includes Diane Deignan, Heather Dominey, and
Susan Furtado.
ACRIN Protocols
Open to Accrual / In Follow-up Phase:
6654 -
Contemporary Screening for the Detection of Lung Cancer
6657 -
MRI in Monitoring Breast Cancer Therapy
6659 - MR
Spectroscopy of the Prostate
6660 -
Whole Body MRI in the Evaluation of Pediatric Malignancies
6661 -
Percutaneous Radiofrequency Ablation of Bone Metastases Using CT
Guidance
6664 -
National CT Colonography Trial
6665 - A
Phase II Trial of Neoadjuvant/Adjuvant STI-571 (Gleevec NSC #716051)
for Primary and Recurrent Operable Malignant GIST Expressing the KIT
Receptor Tyrosine Kinase (CD117)
6666 -
Screening Breast Ultrasound in High-Risk Women
6667 -
MRI Screening of the Contralateral Breast in Women with a Recent
Diagnosis of Breast Cancer
6668 -
Positron Emission Tomography Pre- and Post-treatment Assessment for
Locally Advanced Non-small Cell Lung Carcinoma
6673 -
Multi-center Feasibility Study of Percutaneous Radiofrequency Ablation
of Hepatocellular Carcinoma in Cirrhotic Patients
In Analysis:
6651 -
Role of Radiology in the Pretreatment Evaluation of Invasive Cervical
Cancer
6652 -
Digital vs. Film Screen Mammography (DMIST)
6658 -
CT-Derived Primary Tumor Volume Measurements in Supraglottic
Cancer
6662 -
Semi-automated Calculation of Volumes of Enhancing Tumor and Tumor +
Edema from Routine MR Images in Patients with Malignant
Gliomas
In Development:
6671 -
Utility of Preoperative FDG-PET/CT And Ferumoxtran-10 MRI Scanning
Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal
Lymph Node Metastasis in Patients with Locoregionally Advanced
Carcinoma of the Cervix
6672 -
Comparison of Preoperative Ferumoxtran-10 Enhanced MRI to conventional
MRI in the Detection and Characterization of Pelvic Lymph Nodes in
Patients with Bladder Cancer
6674 - A
Phase II Multi-Center Study of Focused Ultrasound Ablation of Breast
Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of
Ablation
6676 -
The BEST Trial: A Randomized Phase II Study of VEGF, RAF kinase, mTOR,
and EGF-R Targeted Combination Therapy in Advanced Renal Cell
Carcinoma
6677 - MR
Perfusion and Spectroscopy of newly-identified Intra-axial Mass
lesions
6678 -
FDG-PET as a Predictive Marker of Tumor Response and Patient Outcome
in advanced NSCLC Patients
6679 -
FDG-PET/CT in prediction of pathologic response of tumor in patients
with localized esophageal cancer who undergo chemotherapy and/or
chemoradiation prior to surgical resection
|